SCHEDULE: RTW Investments Discloses Stake in Replimune Group

RTW Investments, LP and Roderick Wong report beneficial ownership of 8.9% of Replimune Group, Inc. common stock as of March 31, 2026.

Summary

• RTW Investments, LP, an investment adviser, and Roderick Wong, its Managing Partner and Chief Investment Officer, have filed a Schedule 13G, indicating their beneficial ownership of Replimune Group, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively hold 7,356,916 shares, representing 8.9% of the company's outstanding common stock.
• The shares are held by various RTW Funds, with RTW Investments acting as the investment adviser.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant investment by a known investment firm, but it is a disclosure of existing holdings rather than new strategic information.

Positives

• RTW Investments, a significant investment entity, has taken a notable stake in Replimune Group, potentially signaling confidence in the company's prospects.
• The reporting persons hold shared voting and dispositive power over 7,356,916 shares, indicating substantial influence.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a long-term investment strategy rather than a short-term activist play.

Negatives

• The filing does not contain any negative financial information or operational concerns regarding Replimune Group.
• No specific negative forward-looking statements or risk disclosures are present in this particular filing.

Risks

• The filing does not explicitly detail any current issues or potential future challenges for Replimune Group.
• While not detailed in this filing, as an investment adviser, RTW Investments is subject to market risks and the performance of the funds it manages.

Future Outlook

This filing is primarily a disclosure of beneficial ownership and does not contain specific forward-looking statements or guidance from Replimune Group. The future outlook for the investment itself depends on the performance of Replimune Group's business and the investment strategy of RTW Investments.

Management Comments

• The filing should not be construed as an admission that any of the reporting persons is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
• The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.
• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Industry Context

StockSavvy.ai notes that significant institutional ownership filings like this Schedule 13G can signal investor conviction in the biotechnology sector, which is often characterized by high growth potential and substantial R&D investment. Replimune Group operates in the immuno-oncology space, a highly competitive and dynamic area.

Stakeholder Impact

• Shareholders: The increased visibility from a significant institutional holder like RTW Investments may be viewed positively, potentially attracting further investor interest.
• Management: The filing confirms that the investment is not intended to influence control, suggesting a focus on operational execution by Replimune's management.
• Investment Community: This filing provides transparency regarding significant ownership, aiding analysts and investors in understanding the company's shareholder base.

Next Steps

• RTW Investments and Roderick Wong will continue to hold and manage their investment in Replimune Group, subject to their investment mandates.
• Replimune Group will continue its operations and business development as outlined in its other SEC filings.

Key Dates

Keywords

Replimune Group, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Biotechnology